Indian pharmaceutical leader Lupin Pharma, together with EQT Partners and TPG Capital, has entered early-stage discussions to acquire Vitabiotics, the UK’s largest vitamins and nutraceuticals company.
The deal is reportedly valued at around £1bn (approximately ₹11,800 crore).
Vitabiotics — owned by the Lalvani family — holds one of the strongest portfolios in the global supplements market, with leading brands including Wellwoman, Pregnacare, Menopace, Feroglobin, Perfectil and Osteocare, spanning key segments such as women’s health, paediatrics, immunity and general wellness.
A major attraction for potential buyers is Vitabiotics’ strong Indian footprint via Meyer Vitabiotics, which contributes around 20% of the company’s £253m annual revenue.
The move aligns with India’s rapidly expanding nutraceutical market, driven by rising health awareness and growing demand for vitamins, minerals and wellness supplements.
The interest from Lupin and the PE firms follows earlier consideration from Mankind Pharma and Zydus Wellness, both of which reportedly stepped back due to valuation concerns.
If completed, the acquisition would mark a significant milestone in cross-border UK-India nutraceutical consolidation, signalling increasing pharmaceutical investment into consumer wellness and preventive health markets.